Modality
siRNA
MOA
RAS(ON)i
Target
BCMA
Pathway
DDR
Atopic DermEndometrial Ca
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
~Mar 2019
→ ~Jun 2020
Phase 3
Sep 2020
→ Oct 2031
Phase 3Current
NCT06006842
2,144 pts·Endometrial Ca
2020-09→2028-05·Terminated
NCT08558047
1,252 pts·Atopic Derm
2021-04→2031-10·Recruiting
NCT08012638
1,731 pts·Atopic Derm
2023-11→2030-01·Active
+1 more trial
7,669 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2028-05-282.2y awayPh3 Readout· Endometrial Ca
2030-01-093.8y awayPh3 Readout· Atopic Derm
2030-11-254.7y awayPh3 Readout· Atopic Derm
2031-10-195.6y awayPh3 Readout· Atopic Derm
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
P3
Recruit…
P3
Active
P3
Termina…
Catalysts
Ph3 Readout
2028-05-28 · 2.2y away
Endometrial Ca
Ph3 Readout
2030-01-09 · 3.8y away
Atopic Derm
Ph3 Readout
2030-11-25 · 4.7y away
Atopic Derm
Ph3 Readout
2031-10-19 · 5.6y away
Atopic Derm
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06006842 | Phase 3 | Endometrial Ca | Terminated | 2144 | UPDRS |
| NCT08558047 | Phase 3 | Atopic Derm | Recruiting | 1252 | UPDRS |
| NCT08012638 | Phase 3 | Atopic Derm | Active | 1731 | VA |
| NCT04437767 | Phase 3 | Atopic Derm | Terminated | 2542 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA |